{
  "patent_number": "US 12734215",
  "country": "US",
  "title": "How Modified IL2 Proteins Can Treat Human Diseases",
  "original_title": "Biased IL2 muteins methods and compositions",
  "summary": "This patent describes new versions of the human immune protein Interleukin-2 (IL2), called muteins, designed to specifically target certain immune responses for treating various human diseases.",
  "what_it_does": "This patent generally covers engineered versions of human Interleukin-2 (hIL2), known as muteins, which are proteins modified to have specific, or 'biased,' effects on the immune system. It also includes the pharmaceutical mixtures containing these muteins, the methods for creating these modified proteins, and the genetic tools (recombinant vectors and cells) that carry the instructions for making them. The ultimate goal is to use these biased IL2 muteins as a treatment for human diseases. For example, a specific IL2 mutein might be designed to boost only the anti-tumor immune cells, avoiding side effects on other immune cells.",
  "what_it_does_not_cover": [
    "Does not cover the use of unmodified, natural human Interleukin-2 (hIL2) for therapeutic purposes.",
    "Does not cover other types of immune-modulating proteins or small molecule drugs that are not IL2 muteins.",
    "Does not cover IL2 muteins that are not 'biased' to specifically activate or suppress certain immune cell populations.",
    "Does not cover methods of treatment that do not involve administering these specific IL2 muteins or their formulations.",
    "Does not cover methods for preparing IL2 muteins that do not involve recombinant vectors or cells."
  ],
  "filed": "2022-06-06",
  "granted": "2026-09-15",
  "expires": null,
  "status": "active",
  "holder": null,
  "holder_url": null,
  "inventors": [],
  "times_cited": 0,
  "tags": [
    "biotech",
    "pharmaceutical",
    "gene_editing",
    "oncology",
    "immunology"
  ],
  "abstract": "The present disclosures related to human interleukin-2 (hIL2) muteins, pharmaceutical formulations thereof, methods for preparing interleukin-2 muteins, recombinant vectors and cells comprising nucleic acids encoding IL2 muteins and methods for the treatment of human disease.",
  "url": "https://patentbrief.org/patent/us/12734215/biased-il2-muteins-methods-and-compositions",
  "markdown_url": "https://patentbrief.org/patent/us/12734215/biased-il2-muteins-methods-and-compositions/md",
  "google_patents_url": "https://patents.google.com/patent/US12734215",
  "relatedPatents": [
    {
      "patentNumber": "9481728",
      "countryCode": "US",
      "title": "How Genetically Modified T-Cells Fight CD19 Cancers",
      "url": "https://patentbrief.org/patent/us/9481728/compositions-and-methods-for-treatment-of-cancer"
    },
    {
      "patentNumber": "20250171803",
      "countryCode": "US",
      "title": "Targeting Cancer with CAR T Cells Using Small Molecule 'Flags'",
      "url": "https://patentbrief.org/patent/us/20250171803/methods-and-compositions-for-car-t-cell-therapy"
    },
    {
      "patentNumber": "12163952",
      "countryCode": "US",
      "title": "Predicting and Treating Dangerous Side Effects in CAR T-Cell Therapy",
      "url": "https://patentbrief.org/patent/us/12163952/determining-toxicity-risk-in-car-t-cell-therapy"
    },
    {
      "patentNumber": "9328156",
      "countryCode": "US",
      "title": "How Genetically Modified T-Cells Attack Cancer",
      "url": "https://patentbrief.org/patent/us/9328156/use-of-chimeric-antigen-receptor-modified-t-cells-to-treat-cancer"
    },
    {
      "patentNumber": "20240165159",
      "countryCode": "US",
      "title": "Targeting Cancer with CAR T Cells Using a Chemical Tag",
      "url": "https://patentbrief.org/patent/us/20240165159/compositions-and-methods-for-car-t-cell-therapy"
    }
  ]
}